2018 DCVAC/PCa (SOTIO) Drug Analysis - ResearchAndMarkets.com

Loading...
Loading...

The "Drug Analysis: DCVAC/PCa" drug pipelines has been added to ResearchAndMarkets.com's offering.

DCVAC/PCa (SOTIO) is a cell-based cancer vaccine composed of autologous dendritic cells which are activated to recognize a prostate cancer cell line. When infused into patients, the primed dendritic cells cause activation of T cells, which can then recognize and destroy prostate cancer tumor cells.

Key Topics Covered:

List of Figures

Figure 1: DCVAC/PCa for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of DCVAC/PCa for prostate cancer

Figure 3: Drug assessment summary of DCVAC/PCa for prostate cancer

Figure 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: DCVAC/PCa drug profile

Table 2: DCVAC/PCa Phase III trial in prostate cancer

Table 3: DCVAC/PCa Phase I/II data in prostate cancer

Table 4: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country M, 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/slm633/2018_dcvacpca?w=4

Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...